Weiss Multi-Strategy Advisers’s SpringWorks Therapeutics SWTX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-73,396	Closed	-$1.92M	–	721
2023 Q2	$1.92M	Buy	73,396 +33,912	+86%	+$891K	0.04%	474
2023 Q1	$1.02M	Buy	+39,484	New	+$1.15M	0.02%	510

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Weiss Multi-Strategy Advisers's SWTX Position: Q3 2023 in Review

Weiss Multi-Strategy Advisers sold out of SpringWorks Therapeutics (SWTX) in Q3 2023, closing a stake of 73,396 shares — an estimated $1.92M sold.

Weiss Multi-Strategy Advisers first reported a position in SWTX in Q1 2023 and held it in 2 quarters. The position peaked at $1.92M in Q2 2023. 147 funds tracked by Wall St. Rank hold SWTX as of Q3 2023.

Weiss Multi-Strategy Advisers reported no remaining SpringWorks Therapeutics position as of Q3 2023 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 73,396 SpringWorks Therapeutics shares in Q3 2023, an estimated $1.92M.
Weiss Multi-Strategy Advisers first reported a position in SpringWorks Therapeutics in Q1 2023 and held it in 2 quarters.
Weiss Multi-Strategy Advisers's SpringWorks Therapeutics position peaked at $1.92M in Q2 2023.
147 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2023.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.